Xinshuaike reduces price to prepare for war

In the transitional period of Gansu Province, the bidding results of new base drugs have started to be purchased online Xinlitai (002294 SZ) temporarily locked in the winning bid, and two specifications of clopidogrel bisulfate tablets have all won the bid However, xinshuaike, a newly acquired subsidiary of Lepu medical (300003 SZ), failed to purchase online due to its higher price limit In response, xinshuaike, who is specially in charge of bidding in Gansu, told the big smart news agency that "according to the price limit set by the province, the company has resubmitted the application for quotation" Based on the analysis of the bid winning results of transition base drugs in Gansu Province, three old competitors of clopidogrel bisulfate tablets appeared in the catalog, among which, two specifications of xinlitai 25mg and 75mg won the bid in Yuan and yuan respectively; the original manufacturer Sanofi won the bid in yuan, which was only used by medical institutions above the county level due to the high price However, xinshuaike, who has been entering the base drug market at a low price, has made an abnormal situation The prices of 25mg and 75mg are RMB and RMB respectively, which are higher than the price limit of RMB and RMB respectively, thus losing the chance of winning the bid New Shuaike has now seized the opportunity of second quotation and declared the price to be reduced to the limit price, which means that the company can still enter Gansu market at a lower price In June this year, Lepu medical wholly acquired Henan xinshuaike and began to enter the field of cardiovascular drugs Pu Zhongjie, the founder and general manager of Lepu medical, once said that in the future, "shuaixin" will be 6 or 7 percentage points lower than "Taijia" of its main competitor, xinlitai At present, "Shuai Xin" only won the bidding in Anhui county hospital.